Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Journal Article (Journal Article;Multicenter Study)

BACKGROUND: Use of the recombinant proteins NefTat and gp120(W61D) formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system. METHODS: Eighty-four HIV uninfected human participants were vaccinated intramuscularly at 0, 1, and 3 months and evaluated for safety. Immune responses were analyzed for the presence of vaccine-induced antibody and T lymphocyte responses. RESULTS: The vaccines were safe and well tolerated at all doses. Nef-, Tat-, and gp120-specific binding antibodies were induced in all individuals that received the respective antigen, lasting up to 9 months after the final immunization. Antibodies able to neutralize the T-cell laboratory-adapted strain of HIV-1(W61D) were detected in the majority of vacinees, but did not neutralize primary isolates. Envelope-specific antibody-dependent cell cytoxicity was detected in most of the individuals receiving gp120. Robust and persistent HIV-specific lymphoproliferative responses were detected against all subunit proteins in the majority of immunized participants. As expected, HIV-specific CD8 T-cell responses were not detected. CONCLUSIONS: Despite the lack of primary isolate neutralizing antibody induction, the observed high frequency and magnitude of other immune responses warrant further work with this vaccine or vaccine components.

Full Text

Duke Authors

Cited Authors

  • Goepfert, PA; Tomaras, GD; Horton, H; Montefiori, D; Ferrari, G; Deers, M; Voss, G; Koutsoukos, M; Pedneault, L; Vandepapeliere, P; McElrath, MJ; Spearman, P; Fuchs, JD; Koblin, BA; Blattner, WA; Frey, S; Baden, LR; Harro, C; Evans, T; NIAID HIV Vaccine Trials Network,

Published Date

  • January 5, 2007

Published In

Volume / Issue

  • 25 / 3

Start / End Page

  • 510 - 518

PubMed ID

  • 17049679

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2006.07.050


  • eng

Conference Location

  • Netherlands